Albendazole

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Eskazole; Bulgaria: Zentel; Cyprus: Zestaval; France: Eskazole, Zentel; Germany: Eskazole; Greece: Albendazole, Albendol; Italy: Zentel; Netherlands: Eskazole; Poland: Zentel; Portugal: Zentel; Romania: Albendazol, Albendol, Duador, Eskazole, Vermigal, Zentel; Slovakia: Zentel; Spain: Eskazole.

North America

USA: Albenza.

Latin America

Argentina: Albendazol, Vastus, Vermizole; Brazil: Alba-3, Albel, Albendazol, Albendy, Albentel, Albenzonil, Alin-Millet Roux, Benzol-Greenpharma, Imavermil, Mebenix, Monozol, Neo Bendazol, Parasin, Vermiclase, Vermital, Zentel, Zolben; Mexico: Albendazol, Aldamín, Alfazol, Bradelmín, Dazocán, Dazolin, Dezabil, Digezanol, Eskazole, Euralbén, Gascop, Ilides, Kolexán, Loveral, Lumbrifar, Lurdex, Rivazol, Serbendazol, Synparyn, Tenibex, Veranzol, Vermin Plus, Vermisen, Zelfín, Zenaxín, Zentel.

Asia

Japan: Eskazole.

Drug combinations

Chemistry

Albendazole: C~12~H~15~N~3~O~2~S. Mw: 265.33. (1) Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; (2) Methyl 5-(propylthio)-2-benzimidazolecarbamate. CAS-54965-21-8 (1976).

Pharmacologic Category

Anti-Infective Agents; Anthelmintics. (ATC-Code: P02CA03).

Mechanism of action

Causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of helminths and larvae, causing worm death.

Therapeutic use

Treatment of parenchymal neurocysticercosis caused by Cysticercus cellulosae, the larval form of Taenia solium (pork tapeworm) and cystic hydatid disease of the liver, lung, and peritoneum caused by Echinococcus granulosus.

Pregnancy and lactiation implications

Contraindicated during pregnancy. Breast-feeding is not recommended during therapy.

Unlabeled use

Has activity against Ascaris lumbricoides (roundworm), Ancylostoma caninum, Ancylostoma duodenale, Necator americanus (hookworms), cutaneous larva migrans, Enterobius vermicularis (pinworm), Gnathostoma spinigerum, Gongylonema sp, Mansonella perstans (filariasis), Opisthorchis sinensis (liver fluke), Visceral larva migrans (toxocariasis), Clonorchis sinensis liver fluke, Giardia lamblia, Cysticercus cellulosae, Echinococcus multilocularis. Treatment of intestinal microsporidiosis (Encephalitozoon intestinalis), disseminated microsporidiosis (E. hellem, E. cuniculi, E. intestinalis, Pleistophora sp, Trachipleistophora sp, Brachiola vesicularum). Ocular microsporidiosis (E. hellem, E. cuniculi, Vittaforma corneae).

Contraindications

Hypersensitivity to albendazole, benzimidazoles, or any component of the formulation.

Warnings and precautions

Bone marrow suppression (agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, and pancytopenia) may occur. Use with caution in hepatic impairment (more susceptible to hematologic toxicity). Transaminase elevations have occurred (patients with abnormal LFTs and hepatic echinococcosis are at an increased risk of hepatotoxicity). Patients treated for neurocysticercosis should receive corticosteroid administration (in order to minimize inflammatory reactions and prevent cerebral hypertension).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart